PMID- 26469771
OWN - NLM
STAT- MEDLINE
DCOM- 20171229
LR  - 20211204
IS  - 1365-2125 (Electronic)
IS  - 0306-5251 (Print)
IS  - 0306-5251 (Linking)
VI  - 82
IP  - 5
DP  - 2016 Nov
TI  - Targeting molecules to medicine with mTOR, autophagy and neurodegenerative 
      disorders.
PG  - 1245-1266
LID - 10.1111/bcp.12804 [doi]
AB  - Neurodegenerative disorders are significantly increasing in incidence as the age 
      of the global population continues to climb with improved life expectancy. At 
      present, more than 30 million individuals throughout the world are impacted by 
      acute and chronic neurodegenerative disorders with limited treatment strategies. 
      The mechanistic target of rapamycin (mTOR), also known as the mammalian target of 
      rapamycin, is a 289 kDa serine/threonine protein kinase that offers exciting 
      possibilities for novel treatment strategies for a host of neurodegenerative 
      diseases that include Alzheimer's disease, Parkinson's disease, Huntington's 
      disease, epilepsy, stroke and trauma. mTOR governs the programmed cell death 
      pathways of apoptosis and autophagy that can determine neuronal stem cell 
      development, precursor cell differentiation, cell senescence, cell survival and 
      ultimate cell fate. Coupled to the cellular biology of mTOR are a number of 
      considerations for the development of novel treatments involving the fine control 
      of mTOR signalling, tumourigenesis, complexity of the apoptosis and autophagy 
      relationship, functional outcome in the nervous system, and the intimately linked 
      pathways of growth factors, phosphoinositide 3-kinase (PI 3-K), protein kinase B 
      (Akt), AMP activated protein kinase (AMPK), silent mating type information 
      regulation two homologue one (Saccharomyces cerevisiae) (SIRT1) and others. 
      Effective clinical translation of the cellular signalling mechanisms of mTOR 
      offers provocative avenues for new drug development in the nervous system 
      tempered only by the need to elucidate further the intricacies of the mTOR 
      pathway.
CI  - (c) 2015 The British Pharmacological Society.
FAU - Maiese, Kenneth
AU  - Maiese K
AD  - Cellular and Molecular Signaling, Newark, New Jersey, 07101, USA. 
      wntin75@yahoo.com.
LA  - eng
GR  - RA/ARRA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20151226
PL  - England
TA  - Br J Clin Pharmacol
JT  - British journal of clinical pharmacology
JID - 7503323
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects/*physiology
MH  - Autophagy/*drug effects/physiology
MH  - Humans
MH  - Molecular Targeted Therapy/*methods
MH  - Neurodegenerative Diseases/*drug therapy
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Signal Transduction/*drug effects/physiology
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/physiology
PMC - PMC5061806
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Huntington's disease
OT  - Parkinson's disease
OT  - erythropoietin
OT  - stem cells
OT  - stroke
EDAT- 2015/10/16 06:00
MHDA- 2017/12/30 06:00
PMCR- 2017/11/01
CRDT- 2015/10/16 06:00
PHST- 2015/09/27 00:00 [received]
PHST- 2015/10/11 00:00 [revised]
PHST- 2015/10/13 00:00 [accepted]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2017/12/30 06:00 [medline]
PHST- 2015/10/16 06:00 [entrez]
PHST- 2017/11/01 00:00 [pmc-release]
AID - BCP12804 [pii]
AID - 10.1111/bcp.12804 [doi]
PST - ppublish
SO  - Br J Clin Pharmacol. 2016 Nov;82(5):1245-1266. doi: 10.1111/bcp.12804. Epub 2015 
      Dec 26.